Don’t invest unless you’re prepared to lose all your money invested. Investments in our companies are high-risk investments. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Please take 2 mins to learn more by clicking this link and viewing our summary of key risks.

Screenshot 2023 11 30 at 09 36 57

StemBond Technologies 'one to watch'

Portfolio company StemBond Technologies was recently listed as one to watch

In their 2023 list of 10 Top Regenerative Medicine Startups to Watch, Startus Insights included portfolio company StemBond Technologies.

This is fantastic recognition of the work being done by CEO and Founder Andrew Hodgson and the team as they pursue their mission to make cell therapies highly effective and accessible to all.

StemBond Technologies specialises in advanced materials for cell and tissue culture, giving them the power to influence cell fate and function, resulting in superior cell products at a larger scale.

You can find out more on StemBond Technologies' portfolio page and read more on their Startus listing on the Startus site.